Managing Seborrheic Keratosis: Evolving Strategies and Optimal Therapeutic Outcomes.
Authors: Kao S, Kiss A, Efimova T, Friedman AJ Abstract Seborrheic keratosis (SK) is the most common skin tumor seen by dermatologists in everyday practice. Although the lesions are mostly benign, many patients still elect to have asymptomatic SK removed. The historical standards of treatment are cryosurgery and electrocautery, two surgical options that are effective at lesion removal but have high rates of postoperative adverse events such as treatment-site scarring and pigmentary alterations. The cosmetic outcomes of SK treatment modalities are of keen interest to dermatologists, as the American population become...
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Evaluation of Men's Trends and Experiences in Aesthetic Treatment.
This study suggests that a majority of our male patients have either embraced or are interested in cosmetic treatments, but the cost and time play a big role in their decision. As cosmetic providers, we should reflect a commitment to the male population through marketing efforts and offerings to increase participation in minimally invasive aesthetic procedures. J Drugs Dermatol. 2018;17(9):941-946. PMID: 30235379 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Rheological Properties of Several Hyaluronic Acid-Based Gels: A Comparative Study.
CONCLUSION: Adding lidocaine to HA gels does modify their rheological properties yet this, to a variable extent depending on the product. J Drugs Dermatol. 2018;17(9):948-954. PMID: 30235380 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

The Potential Role of Botulinum Toxin in Improving Superficial Cutaneous Scarring: A Review.
Authors: Dhawan A, Dhawan S, Vitarella D Abstract Botulinum toxins have been utilized in a number of cosmetic and therapeutic applications. One of the more novel uses of botulinum toxin involves its use to mitigate the effects of superficial cutaneous scarring. This is accomplished by decreasing the dynamic tension of a wound by denervating the underlying muscle. Studies have indicated that botulinum toxin serotypes A and B have a positive effect on wound healing and scar appearance. However, larger prospective, blinded, randomized, placebo-controlled clinical trials are required to refine this concept and target o...
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Three-Dimensional Analysis of Minimally Invasive Vacuum-Assisted Subcision Treatment of Cellulite.
CONCLUSION: Utilizing three-dimensional imaging analysis, investigators quantitatively and objectively demonstrated efficacy of a tissue stabilized-guided subcision device in the treatment of cellulite of the buttocks and thighs. J Drugs Dermatol. 2018;17(9):960-965. PMID: 30235382 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Assessing the Potential Role for Topical Melatonin in an Antiaging Skin Regimen.
Authors: Day D, Burgess CM, Kircik LH Abstract BACKGROUND: Melatonin is an endogenous hormone commonly associated with regulation of sleep. However, over the last two decades, research has elucidated a range of effects associated with the compound, including anti-inflammatory, both direct and indirect antioxidant activity, tissue regenerative benefits, and preservation of mitochondrial function. Melatonin's anti-inflammatory and antioxidant support, coupled with its mitochondrial support, make it an intriguing target for use to support skin health. Human skin and hair follicles express functional melatonin receptor...
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

A Randomized, Double-Blind, Placebo-Controlled, Split-Face Study of the Efficacy of Topical Epidermal Growth Factor for the Treatment of Melasma.
CONCLUSIONS: This study suggests that topical EGF is a safe, noninvasive, and effective treatment for melasma. J Drugs Dermatol. 2018;17(6):970-973. PMID: 30235384 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Clinical Efficacy of a Novel Two-Part Skincare System on Pollution-Induced Skin Damage.
Authors: Makino ET, Jain A, Tan P, Nguyen A, Moga A, Charmel C, Kadoya K, Cheng T, Mehta RC Abstract INTRODUCTION: Air pollution continues to be a global health concern and recent studies have shown that air pollutants can cause skin damage and skin aging through several pathways that induce oxidative stress, inflammation, apoptosis, and skin barrier dysfunction. Preventive measures need to be considered to retain optimal skin health, and topical skincare products may be able to alleviate the negative effects of air pollution on skin. A randomized, double-blind, placebo-controlled clinical usage study was conducted...
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Using a New Photo Scale to Compare Product Integration of Different Hyaluronan-Based Fillers After Injection in Human Ex Vivo Skin.
CONCLUSION: The degree of product integration can be assessed and scored according to a 5-grade visual scale based on representative microphotographs. Products with different rheological properties distribute differently when injected into the skin. Firmer gel texture resulted in more targeted product integration whiles softer gel texture resulted in distributed product integration. J Drugs Dermatol. 2018;17(9):982-986. PMID: 30235386 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.
CONCLUSION: The narrow-spectrum antibiotic sarecycline was safe, well tolerated, and effective for moderate to severe acne, with low rates of side effects common with tetracycline antibiotics. J Drugs Dermatol. 2018;17(9):987-996. PMID: 30235387 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

A Single Site, Open Label Clinical Trial, Evaluating the Duration, Efficacy, and Safety of a Novel Lip Plumper.
DISCUSSION: Our study demonstrated that the lip plumping product increased lip volume in almost all patients 15 minutes post-application and showed a continued improvement in lip fullness per investigator assessments 1 hour after application. Adverse events of a tingling or heat sensation were expected and observed as the topical product contained capsaicin, cinnamon, and menthol, all of which can induce this sensation by the release of substance P. J Drugs Dermatol. 2018;17(9):999-1004. PMID: 30235388 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Artificial Intelligence for the Objective Evaluation of Acne Investigator Global Assessment.
In this study, we investigated if Artificial Intelligence trained on images of Acne patients could perform acne grading with high accuracy and reliabilities superior to those of expert physicians. METHODS: 479 patients with acne grading ranging from clear to severe and sampled from three ethnic groups participated in this study. Multi-polarization images of facial skin of each patient were acquired from five different angles using the visible spectrum. An Artificial Intelligence was trained using the acquired images to output automatically a measure of Acne severity in the 0-4 numerical range of the Investigator Global...
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

A Comparative Analysis of Electric and Radiofrequency Microneedling Devices on the Market.
Authors: Puiu T, Mohammad TF, Ozog DM, Rambhatla PV Abstract Microneedling was first described in 1995 by Orentreich and Orentreich for the treatment of atrophic scars and wrinkles.1 The local injury induced by dermal penetration of microneedling causes release of growth factors such as transforming growth factor (TGF)-α, TGF-β, and platelet-derived growth factor (PDGF). This stimulates collagen and elastin fiber production as well as capillary formation, ultimately leading to tissue remodeling.2. PMID: 30235390 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Facial Volumetric Structural Rejuvenation: A Natural Approach to Restoring Youthfulness and Preventing Aging.
Authors: Sadick N Abstract When rejuvenating the face with soft tissue fillers, one must consider its structural framework, and patient specific goals/needs holistically to achieve natural results. PMID: 30235391 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Approach to Skin Lightening in Patients With Melasma.
Authors: Cohen PR Abstract I read with interest the informative article by Spencer et al1 that describes the efficacious use as a novel skin lightening agent (LumaPro-C) for the treatment of patients with melasma. PMID: 30235392 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - September 21, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Medical Bioethics in Dermatologic Procedures
Authors: Alexiades-Armenakas Abstract Abstract: The US Food and Drug Administration (FDA) held a hearing on the safety of dermal fillers in November of 2008 which generated a great deal of media attention and, more importantly, got our attention. The adverse reporting data came from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database and numbered 930 cases over the past 6 years, bringing the complication rate to an estimated 1 in 10 000. Some of the complications were severe, such as facial palsy or anaphylaxis; while others included scarring. Such rare but grave complications are gene...
Source: Journal of Drugs in Dermatology - September 5, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
CONCLUSIONS: High levels of efficacy were maintained through two years of continuous treatment among guselkumab-treated patients, and efficacy improved through two years among adalimumab-treated patients who crossed over to guselkumab at one year. J Drugs Dermatol. 2018;17(8):826-832. PMID: 30124721 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Authors: Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG Abstract Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregulated immune response. In psoriatic skin, expression of all phosphodiesterase 4 (PDE4) isoforms (A-D), part of a family of enzymes known to regulate cyclic adenosine monophosphate levels and immune homeostasis, is elevated compared with healthy controls. Agents that inhibit the enzymatic activity of PDE4, the predominant PDE in most immune cells, exert well-recognized anti-inflammatory effects. Apremilast is a selective PDE4 inhibitor approved...
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
CONCLUSIONS: Adjunctive therapy with Cal/BD foam was associated with an improvement of every measure of disease activity in patients with inadequate response to biologics, an effect that was maintained throughout the study. The majority of patients achieved treat-to-target goals. J Drugs Dermatol. 2018;17(8):845-850. PMID: 30124723 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
CONCLUSIONS: HP/TAZ lotion provides synergistic efficacy that is both rapid and sustained, with good tolerability and safety over 8 weeks use. J Drugs Dermatol. 2018;17(8):855-861. PMID: 30124724 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
CONCLUSION: The HP/TAZ fixed combination lotion provides rapid relief of psoriasis symptoms, with apparent benefits over both HP and TAZ by week 2. J Drugs Dermatol. 2018;17(8):863-868. PMID: 30124725 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
CONCLUSIONS: Toreforant efficacy at 30 and 60 mg was greater than placebo but did not meet predefined success criterion. J Drugs Dermatol. 2018;17(8):873-879. PMID: 30124726 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
This study was conducted to obtain feedback from patients clinically diagnosed with psoriasis regarding their satisfaction following once-daily topical application of the fixed combination calcipotriene (Cal) 0.005% and betamethasone dipropionate (BD) 0.064% foam for 15 days. Patients completed a 13-question online survey. In this community-based setting of patients with mild to severe psoriasis, patients were satisfied with Cal/BD foam after 15 days of use; 94% were satisfied or highly satisfied with symptom relief. Most of the patients (88%) were satisfied with how Cal/BD foam felt on their skin. After 15 days of use, 94...
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Discordance Between Patient Reported Motivations to Seek Treatment for Psoriasis Compared to Television Advertisements.
CONCLUSIONS AND RELEVANCE: While the advertisements assessed in this study did exhibit patient concerns regarding skin appearance, skin symptoms including skin itching, flaking, pain and discomfort were not equally addressed. As these are known factors that motivate psoriasis patients to actively engage in treatment, targeted ads that better demonstrate these concerns may help prompt under-treated patients to seek care. J Drugs Dermatol. 2018;17(8):886-887. PMID: 30124728 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis.
CONCLUSIONS: Topical SB208 was effective and well tolerated in the treatment of tinea pedis. J Drugs Dermatol. 2018;17(8):888-893. PMID: 30124729 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

A Novel, Optimized Method to Accelerate the Preparation of Injectable Poly-L-Lactic Acid by Sonication.
This study established a method to evaluate the distribution of PLLA particles after hydration and found that longer hydration time increased the effective portion (particles less than 60 μm) of PLLA products. Further investigation of the feasibility of reconstitution with sonication revealed that 2-hour hydration of PLLA powders with additional 5-minute-sonication could yield a comparable particle distribution with 48-hour-hydration of PLLA. Moreover, adding lidocaine into the diluent did not alter the distribution of PLLA particles. We proposed a new, feasible and efficient method of preparing PLLA injectable products...
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Cosmetic Versus Medicine: How Does Your Country Define Sunscreen?
Authors: Tong E, Fischer G, Smith SD Abstract Skin cancer (melanoma and non-melanoma) is the most commonly diagnosed cancer in the United States of America, and non-melanoma skin cancer is the most common cause of Australian hospitalisations with cancer as the principle diagnosis, having a huge cost to the country's health care system. Primary and secondary skin cancer prevention is globally inadequate, with only 3 in 10 American adults using sun protection routinely. Evidence suggests that regular sunscreen use in Australians prevents both melanoma and non-melanoma skin cancers, and American research has found tha...
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

UV Protection by Natural Products: C. myrrha Oil Versus Sunscreen.
This study sought to further investigate if C. myrrha oil can confer protection against UV radiation. A UV-sensitive strain of Saccharomyces cerevisiae was grown in petri dishes with one half covered by aluminum foil and the other half covered by clear polyethylene food wrap. The polyethylene half was treated with either SPF 15 or SPF 30 sunscreen, C. myrrha oil or a combination of C. myrrha oil and either sunscreen. The plates were exposed to sunlight. Colony death was quantified using visual estimation. While UV blocking by C. myrrha oil alone was not as effective as that by the synthetic sunscreen, the 1:1 combination o...
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Evaluation of the Performance of a Nature-Based Sensitive Skin Regimen in Subjects With Clinically Diagnosed Sensitive Skin.
CONCLUSIONS: The study demonstrated that NR was effective, well tolerated, and superior to CR in the management of sensitive skin. J Drugs Dermatol. 2018;17(8):908-913. PMID: 30124733 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
Authors: Brown L, Skopit S Abstract KD is an 8 year-old male patient who presented to our clinic in December 2016 with a history of patchy hair loss for many months duration that was worsening. KD's past medical history was notable for atopic dermatitis, and a positive family history of autoimmune thyroid disease. Upon examination he had well circumscribed areas of hair loss throughout his scalp, with exclamation mark hairs seen on dermoscopy. Eyebrows and eyelashes were intact, no epidermal changes of scale or erythema were noted on the scalp and no palpable lymph nodes were present. He was diagnosed with alopecia...
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Treat to Target in Psoriasis: A Real-World Experience With Biologics and Adjunctive Topical Therapy.
Authors: Bagel J Abstract . PMID: 30124735 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Depression? It's the Disease NOT the Drug.
Authors: Kircik LH Abstract Research into the immunopathological mechanisms of plaque psoriasis has produced increasingly targeted biologic therapies. The specificity of these agents allows for high rates of efficacy and decreased adverse events, most notably reduced immune system suppression. In recent years, the recognition of interleukin (IL)-17 as an important component in the pathogenesis of psoriasis has led to the development of a new class of biologics. PMID: 30124736 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab.
Authors: Hashim PW, Chen T, Lebwohl MG, Marangell LB, Kircik LH Abstract Brodalumab, a fully human antibody of the interleukin-17 receptor, is highly effective in the treatment of moderate-to-severe plaque psoriasis. However, based on safety signals identified in clinical trials, brodalumab carries a boxed warning regarding possible risks of suicidal ideation and behavior (SIB). The validity of this link remains controversial, especially in the context of the psoriasis population as well as clinical trial data from other recently approved treatments. Herein, we critically examine the association between brodalumab ...
Source: Journal of Drugs in Dermatology - August 22, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Straight-Line Vector Planning for Optimal Results With Silhouette InstaLift in Minimally Invasive Tissue Repositioning for Facial Rejuvenation.
CONCLUSIONS: Absorbable suspension sutures are a highly adaptable, non-invasive device for lifting and repositioning of descended facial tissue. Outcomes are dependent upon proper technique, including SLVP. J Drugs Dermatol. 2018;17(7):786-793. PMID: 30005090 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content.
CONCLUSIONS: The HDSM-Ax is a well-developed measure of AHH severity based on patient-reported signs and symptoms. It is a superior measure to the HDSS and can be used in clinical research and clinical practice to quantify changes in symptom severity in response to treatment. J Drugs Dermatol. 2018;17(7):707-714. PMID: 30005091 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Nitric Oxide Releasing Nanoparticles as a Strategy to Improve Current Onychomycosis Treatments.
Authors: Costa-Orlandi CB, Mordorski B, Baltazar LM, Mendes-Giannini MJS, Friedman JM, Nosanchuk JD, Friedman AJ Abstract Topical antimicrobials are the ideal mode of onychomycosis treatment for efficient drug delivery and avoidance of sytemic effects associated with oral medications. However, high treatment costs, tissue penetration limitations, and low cure rates have continued to pose major challenges. To capitalize on the progress made by topical efinaconazole solution, efinaconazole was combined with inexpensive, previously-characterized nitric oxide releasing nanoparticles (NO-np), which have been shown to of...
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
CONCLUSIONS: In conclusion, HP 0.01%/TAZ 0.045% lotion provides synergistic efficacy following 8 weeks' therapy that is sustained after a 4-week posttreatment period. J Drugs Dermatol. 2018;17(7):723-726. PMID: 30005093 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Topical Transdermally Delivered Lidocaine and Benzocaine Compared to Compounded Lidocaine/Tetracaine During Microfocused Ultrasound With Visualization Treatment.
CONCLUSIONS: Lidocaine 4% and benzocaine 20% formulations utilizing a novel transdermal delivery system perform similarly to compounded lidocaine 23%/tetracaine 7% for discomfort mitigation during MFU-V treatment. More subjects preferred lidocaine 4%/ benzocaine 20% and rated it as "very effective" vs the compounded product. Fewer treatment pauses due to patient discomfort when using the lidocaine 4%/benzocaine 20% may translate to time efficiency. J Drugs Dermatol. 2018;17(7):729-734. PMID: 30005094 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

The Importance of Early Treatment in Psoriasis and Management of Disease Progression.
Authors: Kerdel F, Don F Abstract Psoriasis is a chronic, immune-mediated, inflammatory disease that if left untreated can result in prolonged subclinical inflammation that affects a variety of organs, including the heart, liver, kidney, and intestines, as well as joints and muscles. Relatedly, psoriasis significantly increases patients' risks for developing certain comorbidities. Disease progression in psoriasis is unpredictable, and some patients have mild disease that is stable for many years, while in others, mild disease quickly progresses to moderate-to-severe psoriasis. Adding to the complexity of this disea...
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Primary Axillary Hyperhidrosis Treatment Using High Intensity Focused Fractional Radiofrequency Microneedling.
We present here a clinical experience summary from three US centers providing hyperhidrosis treatments using the high-intensity radio-frequency device, including treatment parameters, clinical outcomes, and pre- and post-treatment images. J Drugs Dermatol. 2018;17(7):745-748. PMID: 30005096 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
CONCLUSIONS: This study was limited by data for health outcomes and costs over long time periods, particularly stratified by severity. We estimated that dupilumab improved health outcomes compared to usual care but with additional costs, with an ICER below commonly cited thresholds for cost-effectiveness. Dupilumab was projected to be more cost-effective in patients with severe atopic dermatitis, but even in patients with moderate atopic dermatitis, the ICER remained below the upper range of commonly cited thresholds. J Drugs Dermatol. 2018;17(7):750-756. PMID: 30005097 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Clinical Improvements in Very Dry Skin from a Natural Ingredient-Based Moisturizing Cream Compared With a Leading Colloidal Oatmeal Control.
In conclusion, the natural ingredient-based moisturizing cream was highly effective in providing moisturization and improving the skin barrier of subjects with very dry leg skin. It also produced significant improvements in visual dryness and tactile roughness that persisted during regression. Overall, these results show that the natural ingredient-based moisturizing cream delivers comparable benefits to that of a colloidal oatmeal-containing benchmark product and is an option for health care providers and consumers who seek relief from dry skin and prefer a product with all-natural ingredients. J Drugs Dermatol. 2018;17(7...
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Clinical Characteristics of Lower Extremity Surgical Site Infections in Dermatologic Surgery Based Upon 24-Month Retrospective Review.
Authors: Bari O, Eilers RE, Rubin AG, Jiang SIB Abstract Dermatologic surgery performed on the lower extremities has an increased risk for surgical site infections (SSI). Our objective was to evaluate the clinical characteristics associated with SSI following Mohs micrographic surgery (MMS) and wide local excisions (WLE) performed below the knee. We performed a single-center retrospective chart review of patients (n=271) that underwent these procedures. Within 14 days of the lower extremity procedure, four of 175 MMS patients (2.3%) developed SSI compared to eight of 96 WLE patients (8.3%; P=0.029). Subcuticular su...
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Novel Topical Cytokinin Improves Coarse Wrinkles and Skin Roughness Without Skin Irritation.
CONCLUSION: Topical 4HBAP (0.10%) significantly improves the appearance of fine lines and coarse wrinkles, reduces skin roughness, hyperpigmentation, facial erythema, and non-inflammatory acne lesions, and improves skin hydration without any observed side effects. J Drugs Dermatol. 2018;17(7):772-779. PMID: 30005100 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Combined Hyperthermic 1060nm Diode Laser Lipolysis With Topical Skin Tightening Treatment: Case Series.
CONCLUSION: This case series demonstrated that a combined topical skin tightening concentrate with a hyperthermic laser lipolysis device may achieve improved aesthetic outcomes without adverse events. J Drugs Dermatol. 2018;17(7):780-785. PMID: 30005101 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Patient Reported Improvement in Quality of Life Associated With Successful Laser Hair Reduction at Hemodialysis Site With 1064-nm Nd:YAG Laser.
Authors: Thomas LW, Wang EB, Urban J, Jagdeo J Abstract Laser hair reduction is a well-established modality for a wide range of medical indications. Laser hair reduction can be beneficial for hemodialysis patients who undergo repeated adhesive tape application and removal at their hemodialysis site during hemodialysis sessions. There is a paucity of published literature on efficacious laser hair removal treatments for hemodialysis patients. Herein, we present a case of a 50-year-old male (Fitzpatrick III) with end-stage renal disease on hemodialysis, who achieved successful laser hair reduction at his hemodialysis ...
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Combination Ablative Approach to Laser Therapy in Advanced Aging of the Face.
CONCLUSION: For appropriately selected patients, combination fractional ablative CO2 and full-field ablative erbium resurfacing for facial rejuvenation is safe, efficacious and merits consideration. J Drugs Dermatol. 2018;17(7):796-799. PMID: 30005103 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
We present a case series of 11 patients with severe alopecia areata on longstanding, regular to high dose oral tofacitinib with marked hair regrowth. Additionally, we present a case of moderate to severe alopecia areata successfully treated with topical tofacitinib cream. J Drugs Dermatol. 2018;17(7):800-803. PMID: 30005104 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

The Evaluation of Cutaneous Metastasis from an Unknown Primary.
We present the case of a man that had a rapidly growing nodule on his face. Removal of the lesion was more difficult than anticipated because it was tightly adherent to adjacent tissue. Pathology from the lesion showed a malignant neoplasm thought to have arisen at a distant site. The evaluation of this patient may provide insights into the workup for patients that present with cutaneous metastatic malignancies of unknown etiology. In general, these patients need to be fully evaluated in an attempt to locate the primary lesion. When a primary lesion can not be ascertained, careful surveillance of the patient is warranted. ...
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab.
We present a case of a 78-year-old woman with Grade 3 ulcerative oral mucositis that occurred 13 months after initiation of PD-1 inhibitor, pembrolizumab, for the treatment for lung adenocarcinoma. She was successfully treated with prednisone, and pembrolizumab was temporarily held by her oncologist. Physicians should be aware of the possibility of severe mucositis in the setting of PD-1 inhibitors, as well as the management. J Drugs Dermatol. 2018;17(7):807-809. PMID: 30005106 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - July 15, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research